Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 24, 2026
MSFU: Analyzing 2x Leveraged Exposure to Microsoft (MSFT) After a -19% YTD Decline

MSFU: Analyzing 2x Leveraged Exposure to Microsoft (MSFT) After a -19% YTD Decline

Key Takeaways

  • MSFU provides 200% daily leveraged exposure to Microsoft (MSFT) common shares, making it a high-risk, single-stock tactical instrument rather than a diversified ETF.
  • Microsoft shares have declined approximately 19% year-to-date through late July 2026, driven by investor concerns over the return on an estimated $190 billion in annual capital expenditures for AI infrastructure.
  • The fund's leveraged structure means daily compounding effects can cause performance to deviate significantly from 2x Microsoft's return over periods longer than one day, particularly during volatile markets.
  • Microsoft's underlying business momentum remains strong: Azure grew 40% year-over-year, AI annualized revenue surpassed $37 billion, and the commercial backlog reached $627 billion.
  • Upcoming earnings on July 29, 2026, and any shift in sentiment around AI monetization represent the most consequential near-term catalysts for MSFU.

MSFU Overview

The Direxion Daily MSFT Bull 2X ETF (MSFU) is a leveraged single-stock exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of Microsoft Corporation (MSFT) common shares. Launched in September 2022 and listed on Nasdaq, the fund is managed by Direxion and carries a net expense ratio of 0.98%.

Unlike broadly diversified equity ETFs, MSFU is a concentrated, non-diversified vehicle that achieves its leveraged exposure primarily through swap agreements with major global financial institutions, alongside direct holdings of Microsoft stock, U.S. Treasury securities, and cash management instruments. The portfolio holds approximately 10 to 11 positions, with Microsoft equity representing roughly 15–16% of net assets and swap contracts providing the additional leveraged exposure. The fund's total net assets stood at approximately $860 million to $940 million as of mid-2026, with average daily trading volume in the range of 6 to 9 million shares. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the leveraged ETF space.

Because MSFU resets its leverage daily, it is designed for short-term tactical use by experienced traders. Over multi-day or multi-week holding periods, the compounding of daily returns—especially during periods of elevated volatility—can produce returns that differ materially from 200% of Microsoft's cumulative performance. The fund is not suitable for buy-and-hold investors.

Industry and Thematic Landscape

MSFU's fortunes are entirely tethered to Microsoft, which sits at the intersection of several dominant investment themes: artificial intelligence, cloud computing, enterprise software, and the broader technology sector rotation that has shaped equity markets throughout 2026.

The macroeconomic backdrop has been defined by persistently elevated interest rates, which continue to pressure valuation multiples across the technology sector. The Federal Reserve has maintained a cautious stance on rate cuts, keeping the cost of capital higher than many investors anticipated entering the year. This has disproportionately affected high-duration growth stocks, including Microsoft, even as the company's fundamental performance has remained robust.

Within the AI theme, investor sentiment has shifted from enthusiasm about infrastructure buildout toward demanding clearer evidence of monetization. Microsoft's aggressive capital expenditure program—the centerpiece of its AI strategy—has drawn scrutiny as free cash flow growth has decelerated. This dynamic has created a tug-of-war between Microsoft's strong revenue momentum in Azure and AI services and market skepticism about the ultimate return on those investments. The broader Magnificent Seven group has also faced headwinds, though Microsoft has underperformed its mega-cap peers, making it the weakest performer in that cohort so far this year.

Performance and Positioning Snapshot

MSFU has experienced substantial declines in 2026, reflecting the amplified effect of Microsoft's approximately 19% year-to-date drop. Over the last 30 days, MSFU has traded in a wide range between roughly $19.88 and $25.51, with the underlying Microsoft shares showing modest recovery from their June 24 low of $349.20 to around $382 as of late July. Despite recent stabilization, the fund's 52-week range—from $19.47 to $61.16—illustrates the extreme volatility inherent in a 2x leveraged single-stock product.

Over the trailing three-month period, MSFU has declined sharply, consistent with Microsoft's own pullback from levels above $420 in late April. The primary driver has been the market's recalibration of AI-related growth expectations. Microsoft's Q3 2026 earnings—released in late April—delivered an 18% year-over-year revenue increase to $82.9 billion and diluted earnings per share (EPS) of $4.27, both beating consensus estimates. However, the report also highlighted that capital expenditures had surged 84% year-over-year to approximately $30.9 billion for the quarter, exacerbating concerns about margin compression and the timeline for AI returns.

Institutional positioning has added another layer of complexity. While institutional buying of Microsoft still outweighs selling by a ratio of more than 3:1, the pace of accumulation slowed notably during the first half of 2026, giving sellers an edge in price discovery. ETF flows into MSFU have been mixed, with periods of elevated trading volume around Microsoft's earnings and AI-related announcements. The fund's dividend yield, which appears elevated at times due to the declining share price, reflects distribution mechanics rather than income-oriented strategy.

Enhancing Research with Tickeron’s AI Screener

When evaluating leveraged products like MSFU or scanning for complementary ideas in the broader market, I find Tickeron’s AI Screener to be a practical addition to the workflow. It applies artificial intelligence across technical indicators, fundamentals, volatility metrics, and pattern recognition to surface securities that meet specific criteria. In practice, this helps narrow the field efficiently when comparing single-stock leveraged ETFs against sector peers or identifying potential hedges during periods of uncertainty.

2026 Outlook and Key Factors to Monitor

Looking ahead, the most critical event for MSFU is Microsoft's upcoming quarterly earnings report scheduled for July 29, 2026. Analysts expect revenue of approximately $87.7 billion and EPS around $4.24. Azure growth, currently at 40%, will be the most closely watched metric, alongside any guidance updates regarding capital expenditure plans and AI revenue run rates. A sustained acceleration in Azure or evidence that AI infrastructure spending is translating into higher-margin recurring revenue could serve as a powerful catalyst.

Macroeconomic conditions will remain pivotal. Any shift in the Federal Reserve's posture toward rate cuts would likely benefit Microsoft's valuation multiple and, by extension, MSFU. Conversely, if inflation proves stickier than anticipated and rates stay higher for longer, technology stocks could face continued multiple compression.

On the structural side, Microsoft's $627 billion commercial backlog provides a substantial revenue runway, while the company's Copilot product suite and expanding enterprise AI partnerships—including recent agreements with major financial institutions—represent longer-term growth vectors. However, regulatory risk has not disappeared; securities class-action lawsuits related to AI and Copilot disclosures could add headline risk. For MSFU investors, the combination of a leveraged daily reset structure, single-stock concentration, and an uncertain macroeconomic environment demands rigorous risk management and active position monitoring.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: MSFU

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for MSFU turns positive, indicating new upward trend

MSFU saw its Momentum Indicator move above the 0 level on July 30, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 66 similar instances where the indicator turned positive. In of the 66 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for MSFU just turned positive on July 02, 2026. Looking at past instances where MSFU's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

MSFU moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MSFU crossed bullishly above the 50-day moving average on July 31, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where MSFU advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 223 cases where MSFU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

MSFU broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Microsoft Corp (NASDAQ:MSFT).

Industry description

The investment seeks daily investment results, before fees and expenses, of 200% of the daily performance of MSFT. The fund will enter into one or more swap agreements with major global financial institutions whereby the fund and the global financial institution will agree to exchange the return earned on an investment by the fund invests in MSFT that is equal, on a daily basis, to 200% of the value of the fund's net assets. It is non-diversified.

High and low price notable news

The average weekly price growth across all stocks in the Direxion Daily MSFT Bull 2X Shares ETF was 8%. For the same ETF, the average monthly price growth was 31%, and the average quarterly price growth was 26%. MSFT experienced the highest price growth at 11%, while MSFT experienced the biggest fall at 11%.
View a ticker or compare two or three
MSFU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.